Colorimetric aptasensor coupled with a deep-learning-powered smartphone app for programmed death ligand-1 expressing extracellular vesicles by Adeel Khan, Adeel Khan, Haroon Khan, Nongyue He, Zhiyang Li, Heba Khalil Alyahya, Yousef A. Bin Jardan

Subjects: Get full text

Prognostic value of tumor‐infiltrating lymphocytes and PD‐L1 expression in esophageal squamous cell carcinoma by Jie Hu, Takeshi Toyozumi, Kentaro Murakami, Satoshi Endo, Yasunori Matsumoto, Ryota Otsuka, Tadashi Shiraishi, Shinichiro Iida, Hiroki Morishita, Tenshi Makiyama, Yuri Nishioka, Masaya Uesato, Koichi Hayano, Akira Nakano, Hisahiro Matsubara

Subjects: Get full text

IL-17 triggers PD-L1 gene transcription in NSCLC cells via TRIM31-dependent MEF2C K63-linked polyubiquitination by Shuai Ying, Ningxia Wu, Yuting Ruan, Wen Ge, Pei Ma, Tongpeng Xu, Yongqian Shu, Yingwei Wang, Wen Qiu, Chenhui Zhao

Subjects: Get full text

Case report: A case of type 1 diabetes with diabetic ketoacidosis induced by envafolimab treatment in hepatocellular carcinoma by Youjia Li, Kai Qu, Xiuli Li, Xin Yang, Kanghuai Zhang, Jiao Xie

Subjects: “…PD-L1…”
Get full text

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer by Cecilia Olsson Ladjevardi, Marcus Skribek, Anthoula Koliadi, Viktoria Rydén, Ali Inan El-Naggar, Evangelos Digkas, Antonios Valachis, Gustav J. Ullenhag

Subjects: Get full text

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy by Myrna Luna-Gutiérrez, Erika Azorín-Vega, Rigoberto Oros-Pantoja, Blanca Ocampo-García, Pedro Cruz-Nova, Nallely Jiménez-Mancilla, Gerardo Bravo-Villegas, Clara Santos-Cuevas, Laura Meléndez-Alafort, Guillermina Ferro-Flores

Subjects: Get full text

Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1 by Coco Duizer, Moniek Salomons, Merel van Gogh, Sanne Gräve, Freke A. Schaafsma, Maaike J. Stok, Merel Sijbranda, Raghuvandhanan Kumarasamy Sivasamy, Rob J. L. Willems, Marcel R. de Zoete

Subjects: Get full text

Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer by Huiping Qiang, Yue Wang, Yao Zhang, Jingwen Li, Lincheng Zhang, Huawei Du, Xuxinyi Ling, Shuhui Cao, Yan Zhou, Runbo Zhong, Hua Zhong

Subjects: Get full text

A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report by Jingjing Chai, Jiaqi Lv, Jian Xiong, Xiuwen Chen, Senyuan Luo, Zhiguo Luo, Zhiguo Luo, Ming Luo

Subjects: Get full text

Dual-release hydrocortisone treatment improves serum and peripheral blood mononuclear cell inflammatory and immune profiles in patients with autoimmune primary adrenal insufficienc... by Laura Tomasello, Antonina Coppola, Giuseppe Pizzolanti, Giuseppe Pizzolanti, Carla Giordano, Giorgio Arnaldi, Valentina Guarnotta

Subjects: Get full text

The impact of PD-L1 expression status on the prognosis of ALK-positive lung cancer patients by Li Wang, Yingjun Kong, Yao Zhang, Chuanyong Mu

Subjects: Get full text

Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors by Zixi Wu, Junbiao Zhang, Le Li, Zhihua Wang, Chunguang Yang

Subjects: Get full text

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison by Wei Chen, Wei Chen, Soichiro Yoshida, Noriyoshi Miura, Shohei Fukuda, Hiroshi Fukushima, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii

Subjects: Get full text

Sinonasal small-cell carcinoma combined concurrently with small-cell lung carcinoma: case report and literature review by Rencui Quan, Rencui Quan, Ling Han, Shihai Wu, Xianming Li

Subjects: Get full text

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung canc... by Ke Wang, Ke Wang, Chuangjie Zheng, Chuangjie Zheng, Xinrong Chen, Xinrong Chen, Penghui Lin, Mengge Lin, Cuizhen Chen, Linzhu Zhai

Subjects: Get full text

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients by Ting Yan, Minghui Long, Chaoyi Liu, Jiwen Zhang, Jiwen Zhang, Xingyu Wei, Xingyu Wei, Fei Li, Fei Li, Dehua Liao

Subjects: “…PD-1/PD-L1 inhibitors…”
Get full text

Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancreatic cancer patients by Tara Seery, Lennie Sender, Omid Jafari, Frank Jones, Patricia Spilman, Sandeep B. Reddy, Patrick Soon-Shiong

Subjects: Get full text

Repression of the stress granule protein G3BP2 inhibits immune checkpoint molecule PD‐L1 by Yanhong Zhang, Changli Yue, Anna M. Krichevsky, Igor Garkavtsev

Subjects: Get full text

Cyclooxygenase-2/prostaglandin E2 inhibition remodulated photodynamic therapy-associated immunosuppression for enhanced cancer immunotherapy by Tao Xu, Kehan Liu, Shuqi Mi, Yao Yao, Mengyao Zhang, Shujuan Xue, Feng Zhi, Sally-Ann Cryan, Dawei Ding

Subjects: Get full text

A panel of cancer testis antigens in squamous cell carcinoma of the lung, head and neck, and esophagus: implication for biomarkers and therapeutic targets by Lin Li, Xin Zhang, Jiayao Yan, Jingyi Guo, Fangcen Liu, Xiao Wei, Qin Liu, Kongcheng Wang, Baorui Liu

Subjects: Get full text